Why the study?
Does preoperative trimetazidine therapy reduce postoperative myocardial injury markers in patients undergoing CABG?
Population
Patients undergoing coronary artery bypass grafting (CABG) (6 RCTs)
Comparison
Preoperative trimetazidine therapy vs Control (no trimetazidine)
Design
Meta-analysis
Follow-up
Postoperative (≤12 or >12 hours after CABG)
Authors
Loading...
Supports preoperative trimetazidine to attenuate myocardial injury in CABG; strengthens pooled RCT evidence for perioperative cardioprotection.
Does preoperative trimetazidine therapy reduce postoperative myocardial injury markers in patients undergoing CABG?
Preoperative trimetazidine therapy significantly reduces postoperative biochemical markers of myocardial injury in patients undergoing CABG.
Zhang et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: